Navigation Links
Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences
Date:5/21/2010

BETHESDA, Md., May 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that updates on several of its BiTE antibody development programs will be made at two upcoming medical conferences.

Blinatumomab (MT103), the Company's lead product candidate, will be the subject of two oral presentations at the 15th Annual Congress of the European Hematology Association, to be held June 10 – 13 in Barcelona.  

In a presentation titled Prolonged Leukemia Free Survival Following Blinatumomab Treatment of Patients with Minimal Residual Disease of B Precursor ALL: Updated Results of a Phase 2 Study (abstract # 1700), Professor Ralf Bargou, Division of Hematology and Oncology, Department of Internal Medicine II, Wurzburg University Hospital, will report updated data from a Phase 2 trial of blinatumomab in patients with MRD-positive acute lymphoblastic leukemia (ALL).  Dr. Bargou, the study's principal investigator, will present updated duration of response data on 19 evaluable patients on June 12 from 4:30 – 4:45 PM CET.  Earlier results from this trial provided the basis for a pivotal trial that the Company plans to initiate in the third quarter of this year.

In a presentation titled CD3/CD19 bispecific BiTE® Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients: 60 micrograms/square meter/d by Continuous Infusion is Toler
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ... field of regenerative medicine, announced today that it ... to investors on Tuesday, July 29, 2014, at ... will include an overview of Asterias, business strategy ... visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes ...
(Date:7/24/2014)... forces worldwide rely on sophisticated equipment, trained personnel, ... public areas against terrorist attacks. A revolutionary new ... to make their job much easier. , The ... of Tel Aviv University ,s School of Chemistry ... by the Herzliya company Tracense, picks up the ...
(Date:7/24/2014)... computers have yet to materialise. Yet, scientists are ... such computers faster. One such approach relies on ... by applying an electric field. A new study ... coupled quantum dots (TQDs) with electrical impulses can ... example, should TQDs be used as quantum information ...
(Date:7/24/2014)... synthetic processes prefer to settle into equilibriuma state ... within the realm of non-equilibrium conditions where new ... energy and phases, such as temperature fluctuations, freezing ... to regulate their body temperature, airplanes to fly, ... , But even though these conditions exist ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2
... BASEL, Switzerland, April 17 Syngenta today,announced that it ... in,Beijing, China. Its focus will be on early-stage evaluation ... corn and soy, in the areas of yield,improvement, drought ... facility will have a global scope and will complement,Syngenta,s ...
... NexGenix Pharmaceuticals, presented,data on its Hsp90 inhibitor program ... San Diego today. The company presented data in ... novel, radicicol-based,Hsp90 inhibitors in its compound series., ... models,without evidence for liver and kidney toxicity. The ...
... Offers a Complete Solution for the Study of ... ... (Nasdaq:,SIAL) today announced the launch of its Imprint(TM) Chromatin,Immunoprecipitation Kit ... a complete,solution for Chromatin Immunoprecipitation, including columns and reagents,for DNA ...
Cached Biology Technology:Syngenta To Build Major Global Biotech Research Center in Beijing, China 2Syngenta To Build Major Global Biotech Research Center in Beijing, China 3NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research 2Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research 3
(Date:7/24/2014)... how wildlife loss leads to conflict among people around ... Conservation Society (WCS) Health & Ecosystems: Analysis of Linkages ... interdisciplinary approach to tackle global biodiversity decline. , The ... the world,s people and provides protein for more than ... as no surprise that today,s unprecedented loss of wildlife, ...
(Date:7/24/2014)... -- The Geneva Healthcare Suite, an innovative technology platform ... room wait times by an average of 92 minutes ... to a recent study published in the Academic Emergency ... suite to access data from incoming patients, implanted cardiac ... Geneva,s technology platform we have been able to quickly ...
(Date:7/24/2014)... native animal species for food or commercial food sale, ... in the decline of many species of primates and ... more than half of the species being consumed are ... surveying not only the meat made available for sale ... forest by hunters and brought to villages for consumption, ...
Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... plants is determined by pigments such as aurones, anthocyanins, ... displayed is dependent not only on the pigment present, ... of metal ions, and pH, among others. Information about ... plant geneticists to engineer new hues, adding to the ...
... hunted to local extinction more than a century ago and ... whales of mainland New Zealand are coming home. A ... that whales from a small surviving population around remote, sub-Antarctic ... mainland. Before the onslaught of 19th century whaling, historical ...
... Mary, University of London, sheds new light on why people ... suffer organ damage in parts of the body which are ... in Nature Immunology *, examines the way certain white ... defend damaged organs against injury or infection. This is ...
Cached Biology News:Engineering blue-hued flowers 2Fighting back from extinction, New Zealand right whale is returning home 2Fighting back from extinction, New Zealand right whale is returning home 3Rogue blood cells may contribute to post-surgery organ damage 2
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
Request Info...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: